BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2010

View Archived Issues

Dr. Reddy's Laboratories claims new globin transcription factor activators

Read More

Merck & Co. discovers new calcitonin receptor CGRP antagonists

Read More

Merck Serono discovers Aurora kinase inhibitors for cancer therapy

Read More

GlaxoSmithKline claims new antiviral agents for hepatitis C virus infection

Read More

Elan discloses novel gamma-secretase inhibitors

Read More

New GSK-3 autophosphorylation inhibitor shows preclinical promise in neuroregeneration after injury

Read More

Phase II data presented on PROSTVAC-VF immunotherapy in metastatic CRPC

Read More

Novartis identifies a new class of potent antimalarials

Read More

Betrixaban compares well with warfarin in phase II trial in nonvalvular atrial fibrillation

Read More

PLATO substudies assess effects of ticagrelor on arrhythmias and pulmonary function

Read More

Flurpiridaz F18 PET detects coronary artery disease with more specificity than [99mTc] SPECT

Read More

Ablynx advances inhalable ALX-0171 to preclinical studies for RSV infections

Read More

Aradigm completes enrollment in phase II trial of inhaled ciprofloxacin in bronchiectasis

Read More

BioSeek and Ono initiate new multiyear drug discovery collaboration

Read More

BioAlliance obtains approval for Loramyc in 13 additional European countries

Read More

Oramed completes phase IIb trial of oral insulin capsule ORMD-0801 for type 2 diabetes

Read More

FDA sets advisory committee review date for Vivus' Qnexa NDA for obesity

Read More

Cortex Pharmaceuticals sells selected Ampakine compounds to Biovail

Read More

Novelos begins enrollment in phase II trial of NOV-205 in hepatitis C

Read More

Traversa and sanofi-aventis to collaborate on development RNAi delivery technology

Read More

Bayer to update label for oral contraceptive Yasmin in E.U.

Read More

Merck KGaA receives approval for extended use of Erbitux in Japan

Read More

Rotarix vaccine not a threat to public safety states EMA

Read More

New safety information for ITP therapeutic WinRho(R) SDF in Canada

Read More

FDA approves Graceway's Zyclara NDA for actinic keratoses

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Person holding stomach in pain

    Cancer specter looming, Abtect effect in UC wallops Abivax

    BioWorld
    Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing